Imatinib and Gleevec
![Picture](/uploads/1/4/4/6/14460470/9043843.png?530)
Recently, studies have been made on CML cells to try to find a possible treatment that would minimize the effects of - or possible cure - it.
A new drug has been found and tested under the name Gleevec. It involves the use of a competitive inhibitor called Imatinib. When Imatinib binds to the BCR-ABL tyrosine kinase, it inhibits the substrate(s) that activate cell proliferation from occurring and can therefore stop the cancer, at least temporarily.
This drug is still being tested but most researchers receive positive results and many expect the new drug to be used sometime soon.
A new drug has been found and tested under the name Gleevec. It involves the use of a competitive inhibitor called Imatinib. When Imatinib binds to the BCR-ABL tyrosine kinase, it inhibits the substrate(s) that activate cell proliferation from occurring and can therefore stop the cancer, at least temporarily.
This drug is still being tested but most researchers receive positive results and many expect the new drug to be used sometime soon.